Efficacy and Safety of BGG492 in the Treatment of Migraine

A Multi-centre, Randomized, Double-blind, Parallel Group, Active and Placebo Controlled, Proof of Concept Study in Patients With Acute Migraine to Assess the Efficacy, Safety and Tolerability of Single Oral Doses of BGG492

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00892203

Enrollment

Registered

2009-05-04

Start date

2009-04-30

Completion date

2010-08-31

Last updated

2020-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Keywords

Migraine, Headache

Brief summary

This study will assess the efficacy and safety of BGG492 used to treat migraine pain.

Interventions

DRUGBGG492

DRUGSumatriptan

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of moderate to severe migraine for at least 1 year * At least 1 migraine episode, but not more 15 migraine days per month * Past use of triptans * Migraine onset before 50 years of age

Exclusion criteria

* Diagnosis of basilar, ophthalmoplegic or hemiplegic migraine. * More than 6 non-migraine headaches per month * Patients receiving migraine prophylaxis treatment * Patients receiving regular treatment with psychoactive drugs * Smokers * Patients with a very high or low body weight Other protocol-defined inclusion/

Design outcomes

Primary

Measure	Time frame
Reduction in migraine pain	2 hours

Countries

Germany, Spain, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026